Illinois General Assembly - Full Text of SB2341
Illinois General Assembly

Previous General Assemblies

Full Text of SB2341  100th General Assembly

SB2341sam001 100TH GENERAL ASSEMBLY

Sen. Jacqueline Y. Collins

Filed: 5/1/2018

 

 


 

 


 
10000SB2341sam001LRB100 17957 JWD 39529 a

1
AMENDMENT TO SENATE BILL 2341

2    AMENDMENT NO. ______. Amend Senate Bill 2341
 
3    "Section 5. The Illinois Controlled Substances Act is
4amended by changing Sections 102 and 204 as follows:
 
5    (720 ILCS 570/102)  (from Ch. 56 1/2, par. 1102)
6    Sec. 102. Definitions. As used in this Act, unless the
7context otherwise requires:
8    (a) "Addict" means any person who habitually uses any drug,
9chemical, substance or dangerous drug other than alcohol so as
10to endanger the public morals, health, safety or welfare or who
11is so far addicted to the use of a dangerous drug or controlled
12substance other than alcohol as to have lost the power of self
13control with reference to his or her addiction.
14    (b) "Administer" means the direct application of a
15controlled substance, whether by injection, inhalation,
16ingestion, or any other means, to the body of a patient,

 

 

10000SB2341sam001- 2 -LRB100 17957 JWD 39529 a

1research subject, or animal (as defined by the Humane
2Euthanasia in Animal Shelters Act) by:
3        (1) a practitioner (or, in his or her presence, by his
4    or her authorized agent),
5        (2) the patient or research subject pursuant to an
6    order, or
7        (3) a euthanasia technician as defined by the Humane
8    Euthanasia in Animal Shelters Act.
9    (c) "Agent" means an authorized person who acts on behalf
10of or at the direction of a manufacturer, distributor,
11dispenser, prescriber, or practitioner. It does not include a
12common or contract carrier, public warehouseman or employee of
13the carrier or warehouseman.
14    (c-1) "Anabolic Steroids" means any drug or hormonal
15substance, chemically and pharmacologically related to
16testosterone (other than estrogens, progestins,
17corticosteroids, and dehydroepiandrosterone), and includes:
18    (i) 3[beta],17-dihydroxy-5a-androstane, 
19    (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, 
20    (iii) 5[alpha]-androstan-3,17-dione, 
21    (iv) 1-androstenediol (3[beta], 
22        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
23    (v) 1-androstenediol (3[alpha], 
24        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
25    (vi) 4-androstenediol  
26        (3[beta],17[beta]-dihydroxy-androst-4-ene), 

 

 

10000SB2341sam001- 3 -LRB100 17957 JWD 39529 a

1    (vii) 5-androstenediol  
2        (3[beta],17[beta]-dihydroxy-androst-5-ene), 
3    (viii) 1-androstenedione  
4        ([5alpha]-androst-1-en-3,17-dione), 
5    (ix) 4-androstenedione  
6        (androst-4-en-3,17-dione), 
7    (x) 5-androstenedione  
8        (androst-5-en-3,17-dione), 
9    (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- 
10        hydroxyandrost-4-en-3-one), 
11    (xii) boldenone (17[beta]-hydroxyandrost- 
12        1,4,-diene-3-one), 
13    (xiii) boldione (androsta-1,4- 
14        diene-3,17-dione), 
15    (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 
16        [beta]-hydroxyandrost-4-en-3-one), 
17    (xv) clostebol (4-chloro-17[beta]- 
18        hydroxyandrost-4-en-3-one), 
19    (xvi) dehydrochloromethyltestosterone (4-chloro- 
20        17[beta]-hydroxy-17[alpha]-methyl- 
21        androst-1,4-dien-3-one), 
22    (xvii) desoxymethyltestosterone 
23    (17[alpha]-methyl-5[alpha] 
24        -androst-2-en-17[beta]-ol)(a.k.a., madol), 
25    (xviii) [delta]1-dihydrotestosterone (a.k.a.  
26        '1-testosterone') (17[beta]-hydroxy- 

 

 

10000SB2341sam001- 4 -LRB100 17957 JWD 39529 a

1        5[alpha]-androst-1-en-3-one), 
2    (xix) 4-dihydrotestosterone (17[beta]-hydroxy- 
3        androstan-3-one), 
4    (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- 
5        5[alpha]-androstan-3-one), 
6    (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- 
7        hydroxyestr-4-ene), 
8    (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- 
9        1[beta],17[beta]-dihydroxyandrost-4-en-3-one), 
10    (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], 
11        17[beta]-dihydroxyandrost-1,4-dien-3-one), 
12    (xxiv) furazabol (17[alpha]-methyl-17[beta]- 
13        hydroxyandrostano[2,3-c]-furazan), 
14    (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one, ) 
15    (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- 
16        androst-4-en-3-one), 
17    (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- 
18        dihydroxy-estr-4-en-3-one), 
19    (xxviii) mestanolone (17[alpha]-methyl-17[beta]- 
20        hydroxy-5-androstan-3-one), 
21    (xxix) mesterolone (1amethyl-17[beta]-hydroxy- 
22        [5a]-androstan-3-one), 
23    (xxx) methandienone (17[alpha]-methyl-17[beta]- 
24        hydroxyandrost-1,4-dien-3-one), 
25    (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- 
26        dihydroxyandrost-5-ene), 

 

 

10000SB2341sam001- 5 -LRB100 17957 JWD 39529 a

1    (xxxii) methenolone (1-methyl-17[beta]-hydroxy- 
2        5[alpha]-androst-1-en-3-one), 
3    (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- 
4        dihydroxy-5a-androstane)
5    (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy 
6        -5a-androstane)
7    (xxxv) 17[alpha]-methyl-3[beta],17[beta]- 
8        dihydroxyandrost-4-ene), 
9    (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- 
10        methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), 
11    (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- 
12        hydroxyestra-4,9(10)-dien-3-one), 
13    (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- 
14        hydroxyestra-4,9-11-trien-3-one), 
15    (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- 
16        hydroxyandrost-4-en-3-one), 
17    (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- 
18        hydroxyestr-4-en-3-one), 
19    (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  
20        (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- 
21        androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- 
22        1-testosterone'), 
23    (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), 
24    (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- 
25        dihydroxyestr-4-ene), 
26    (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- 

 

 

10000SB2341sam001- 6 -LRB100 17957 JWD 39529 a

1        dihydroxyestr-4-ene), 
2    (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- 
3        dihydroxyestr-5-ene), 
4    (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- 
5        dihydroxyestr-5-ene), 
6    (xlvii) 19-nor-4,9(10)-androstadienedione  
7        (estra-4,9(10)-diene-3,17-dione), 
8    (xlviii) 19-nor-4-androstenedione (estr-4- 
9        en-3,17-dione), 
10    (xlix) 19-nor-5-androstenedione (estr-5- 
11        en-3,17-dione), 
12    (l) norbolethone (13[beta], 17a-diethyl-17[beta]- 
13        hydroxygon-4-en-3-one), 
14    (li) norclostebol (4-chloro-17[beta]- 
15        hydroxyestr-4-en-3-one), 
16    (lii) norethandrolone (17[alpha]-ethyl-17[beta]- 
17        hydroxyestr-4-en-3-one), 
18    (liii) normethandrolone (17[alpha]-methyl-17[beta]- 
19        hydroxyestr-4-en-3-one), 
20    (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- 
21        2-oxa-5[alpha]-androstan-3-one), 
22    (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- 
23        dihydroxyandrost-4-en-3-one), 
24    (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- 
25        17[beta]-hydroxy-(5[alpha]-androstan-3-one), 
26    (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- 

 

 

10000SB2341sam001- 7 -LRB100 17957 JWD 39529 a

1        (5[alpha]-androst-2-eno[3,2-c]-pyrazole), 
2    (lviii) stenbolone (17[beta]-hydroxy-2-methyl- 
3        (5[alpha]-androst-1-en-3-one), 
4    (lix) testolactone (13-hydroxy-3-oxo-13,17- 
5        secoandrosta-1,4-dien-17-oic 
6        acid lactone), 
7    (lx) testosterone (17[beta]-hydroxyandrost- 
8        4-en-3-one), 
9    (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- 
10        diethyl-17[beta]-hydroxygon- 
11        4,9,11-trien-3-one), 
12    (lxii) trenbolone (17[beta]-hydroxyestr-4,9, 
13        11-trien-3-one). 
14    Any person who is otherwise lawfully in possession of an
15anabolic steroid, or who otherwise lawfully manufactures,
16distributes, dispenses, delivers, or possesses with intent to
17deliver an anabolic steroid, which anabolic steroid is
18expressly intended for and lawfully allowed to be administered
19through implants to livestock or other nonhuman species, and
20which is approved by the Secretary of Health and Human Services
21for such administration, and which the person intends to
22administer or have administered through such implants, shall
23not be considered to be in unauthorized possession or to
24unlawfully manufacture, distribute, dispense, deliver, or
25possess with intent to deliver such anabolic steroid for
26purposes of this Act.

 

 

10000SB2341sam001- 8 -LRB100 17957 JWD 39529 a

1    (d) "Administration" means the Drug Enforcement
2Administration, United States Department of Justice, or its
3successor agency.
4    (d-5) "Clinical Director, Prescription Monitoring Program"
5means a Department of Human Services administrative employee
6licensed to either prescribe or dispense controlled substances
7who shall run the clinical aspects of the Department of Human
8Services Prescription Monitoring Program and its Prescription
9Information Library.
10    (d-10) "Compounding" means the preparation and mixing of
11components, excluding flavorings, (1) as the result of a
12prescriber's prescription drug order or initiative based on the
13prescriber-patient-pharmacist relationship in the course of
14professional practice or (2) for the purpose of, or incident
15to, research, teaching, or chemical analysis and not for sale
16or dispensing. "Compounding" includes the preparation of drugs
17or devices in anticipation of receiving prescription drug
18orders based on routine, regularly observed dispensing
19patterns. Commercially available products may be compounded
20for dispensing to individual patients only if both of the
21following conditions are met: (i) the commercial product is not
22reasonably available from normal distribution channels in a
23timely manner to meet the patient's needs and (ii) the
24prescribing practitioner has requested that the drug be
25compounded.
26    (e) "Control" means to add a drug or other substance, or

 

 

10000SB2341sam001- 9 -LRB100 17957 JWD 39529 a

1immediate precursor, to a Schedule whether by transfer from
2another Schedule or otherwise.
3    (f) "Controlled Substance" means (i) a drug, substance,
4immediate precursor, or synthetic drug in the Schedules of
5Article II of this Act or (ii) a drug or other substance, or
6immediate precursor, designated as a controlled substance by
7the Department through administrative rule. The term does not
8include distilled spirits, wine, malt beverages, or tobacco, as
9those terms are defined or used in the Liquor Control Act of
101934 and the Tobacco Products Tax Act of 1995.
11    (f-5) "Controlled substance analog" means a substance:
12        (1) the chemical structure of which is substantially
13    similar to the chemical structure of a controlled substance
14    in Schedule I or II;
15        (2) which has a stimulant, depressant, or
16    hallucinogenic effect on the central nervous system that is
17    substantially similar to or greater than the stimulant,
18    depressant, or hallucinogenic effect on the central
19    nervous system of a controlled substance in Schedule I or
20    II; or
21        (3) with respect to a particular person, which such
22    person represents or intends to have a stimulant,
23    depressant, or hallucinogenic effect on the central
24    nervous system that is substantially similar to or greater
25    than the stimulant, depressant, or hallucinogenic effect
26    on the central nervous system of a controlled substance in

 

 

10000SB2341sam001- 10 -LRB100 17957 JWD 39529 a

1    Schedule I or II.
2    (g) "Counterfeit substance" means a controlled substance,
3which, or the container or labeling of which, without
4authorization bears the trademark, trade name, or other
5identifying mark, imprint, number or device, or any likeness
6thereof, of a manufacturer, distributor, or dispenser other
7than the person who in fact manufactured, distributed, or
8dispensed the substance.
9    (h) "Deliver" or "delivery" means the actual, constructive
10or attempted transfer of possession of a controlled substance,
11with or without consideration, whether or not there is an
12agency relationship.
13    (i) "Department" means the Illinois Department of Human
14Services (as successor to the Department of Alcoholism and
15Substance Abuse) or its successor agency.
16    (j) (Blank).
17    (k) "Department of Corrections" means the Department of
18Corrections of the State of Illinois or its successor agency.
19    (l) "Department of Financial and Professional Regulation"
20means the Department of Financial and Professional Regulation
21of the State of Illinois or its successor agency.
22    (m) "Depressant" means any drug that (i) causes an overall
23depression of central nervous system functions, (ii) causes
24impaired consciousness and awareness, and (iii) can be
25habit-forming or lead to a substance abuse problem, including
26but not limited to alcohol, cannabis and its active principles

 

 

10000SB2341sam001- 11 -LRB100 17957 JWD 39529 a

1and their analogs, benzodiazepines and their analogs,
2barbiturates and their analogs, opioids (natural and
3synthetic) and their analogs, and chloral hydrate and similar
4sedative hypnotics.
5    (n) (Blank).
6    (o) "Director" means the Director of the Illinois State
7Police or his or her designated agents.
8    (p) "Dispense" means to deliver a controlled substance to
9an ultimate user or research subject by or pursuant to the
10lawful order of a prescriber, including the prescribing,
11administering, packaging, labeling, or compounding necessary
12to prepare the substance for that delivery.
13    (q) "Dispenser" means a practitioner who dispenses.
14    (r) "Distribute" means to deliver, other than by
15administering or dispensing, a controlled substance.
16    (s) "Distributor" means a person who distributes.
17    (t) "Drug" means (1) substances recognized as drugs in the
18official United States Pharmacopoeia, Official Homeopathic
19Pharmacopoeia of the United States, or official National
20Formulary, or any supplement to any of them; (2) substances
21intended for use in diagnosis, cure, mitigation, treatment, or
22prevention of disease in man or animals; (3) substances (other
23than food) intended to affect the structure of any function of
24the body of man or animals and (4) substances intended for use
25as a component of any article specified in clause (1), (2), or
26(3) of this subsection. It does not include devices or their

 

 

10000SB2341sam001- 12 -LRB100 17957 JWD 39529 a

1components, parts, or accessories.
2    (t-3) "Electronic health record" or "EHR" means an
3electronic record of health-related information on an
4individual that is created, gathered, managed, and consulted by
5authorized health care clinicians and staff.
6    (t-4) "Emergency medical services personnel" has the
7meaning ascribed to it in the Emergency Medical Services (EMS)
8Systems Act.
9    (t-5) "Euthanasia agency" means an entity certified by the
10Department of Financial and Professional Regulation for the
11purpose of animal euthanasia that holds an animal control
12facility license or animal shelter license under the Animal
13Welfare Act. A euthanasia agency is authorized to purchase,
14store, possess, and utilize Schedule II nonnarcotic and
15Schedule III nonnarcotic drugs for the sole purpose of animal
16euthanasia.
17    (t-10) "Euthanasia drugs" means Schedule II or Schedule III
18substances (nonnarcotic controlled substances) that are used
19by a euthanasia agency for the purpose of animal euthanasia.
20    (u) "Good faith" means the prescribing or dispensing of a
21controlled substance by a practitioner in the regular course of
22professional treatment to or for any person who is under his or
23her treatment for a pathology or condition other than that
24individual's physical or psychological dependence upon or
25addiction to a controlled substance, except as provided herein:
26and application of the term to a pharmacist shall mean the

 

 

10000SB2341sam001- 13 -LRB100 17957 JWD 39529 a

1dispensing of a controlled substance pursuant to the
2prescriber's order which in the professional judgment of the
3pharmacist is lawful. The pharmacist shall be guided by
4accepted professional standards including, but not limited to
5the following, in making the judgment:
6        (1) lack of consistency of prescriber-patient
7    relationship,
8        (2) frequency of prescriptions for same drug by one
9    prescriber for large numbers of patients,
10        (3) quantities beyond those normally prescribed,
11        (4) unusual dosages (recognizing that there may be
12    clinical circumstances where more or less than the usual
13    dose may be used legitimately),
14        (5) unusual geographic distances between patient,
15    pharmacist and prescriber,
16        (6) consistent prescribing of habit-forming drugs.
17    (u-0.5) "Hallucinogen" means a drug that causes markedly
18altered sensory perception leading to hallucinations of any
19type.
20    (u-1) "Home infusion services" means services provided by a
21pharmacy in compounding solutions for direct administration to
22a patient in a private residence, long-term care facility, or
23hospice setting by means of parenteral, intravenous,
24intramuscular, subcutaneous, or intraspinal infusion.
25    (u-5) "Illinois State Police" means the State Police of the
26State of Illinois, or its successor agency.

 

 

10000SB2341sam001- 14 -LRB100 17957 JWD 39529 a

1    (v) "Immediate precursor" means a substance:
2        (1) which the Department has found to be and by rule
3    designated as being a principal compound used, or produced
4    primarily for use, in the manufacture of a controlled
5    substance;
6        (2) which is an immediate chemical intermediary used or
7    likely to be used in the manufacture of such controlled
8    substance; and
9        (3) the control of which is necessary to prevent,
10    curtail or limit the manufacture of such controlled
11    substance.
12    (w) "Instructional activities" means the acts of teaching,
13educating or instructing by practitioners using controlled
14substances within educational facilities approved by the State
15Board of Education or its successor agency.
16    (x) "Local authorities" means a duly organized State,
17County or Municipal peace unit or police force.
18    (y) "Look-alike substance" means a substance, other than a
19controlled substance which (1) by overall dosage unit
20appearance, including shape, color, size, markings or lack
21thereof, taste, consistency, or any other identifying physical
22characteristic of the substance, would lead a reasonable person
23to believe that the substance is a controlled substance, or (2)
24is expressly or impliedly represented to be a controlled
25substance or is distributed under circumstances which would
26lead a reasonable person to believe that the substance is a

 

 

10000SB2341sam001- 15 -LRB100 17957 JWD 39529 a

1controlled substance. For the purpose of determining whether
2the representations made or the circumstances of the
3distribution would lead a reasonable person to believe the
4substance to be a controlled substance under this clause (2) of
5subsection (y), the court or other authority may consider the
6following factors in addition to any other factor that may be
7relevant:
8        (a) statements made by the owner or person in control
9    of the substance concerning its nature, use or effect;
10        (b) statements made to the buyer or recipient that the
11    substance may be resold for profit;
12        (c) whether the substance is packaged in a manner
13    normally used for the illegal distribution of controlled
14    substances;
15        (d) whether the distribution or attempted distribution
16    included an exchange of or demand for money or other
17    property as consideration, and whether the amount of the
18    consideration was substantially greater than the
19    reasonable retail market value of the substance.
20    Clause (1) of this subsection (y) shall not apply to a
21noncontrolled substance in its finished dosage form that was
22initially introduced into commerce prior to the initial
23introduction into commerce of a controlled substance in its
24finished dosage form which it may substantially resemble.
25    Nothing in this subsection (y) prohibits the dispensing or
26distributing of noncontrolled substances by persons authorized

 

 

10000SB2341sam001- 16 -LRB100 17957 JWD 39529 a

1to dispense and distribute controlled substances under this
2Act, provided that such action would be deemed to be carried
3out in good faith under subsection (u) if the substances
4involved were controlled substances.
5    Nothing in this subsection (y) or in this Act prohibits the
6manufacture, preparation, propagation, compounding,
7processing, packaging, advertising or distribution of a drug or
8drugs by any person registered pursuant to Section 510 of the
9Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
10    (y-1) "Mail-order pharmacy" means a pharmacy that is
11located in a state of the United States that delivers,
12dispenses or distributes, through the United States Postal
13Service or other common carrier, to Illinois residents, any
14substance which requires a prescription.
15    (z) "Manufacture" means the production, preparation,
16propagation, compounding, conversion or processing of a
17controlled substance other than methamphetamine, either
18directly or indirectly, by extraction from substances of
19natural origin, or independently by means of chemical
20synthesis, or by a combination of extraction and chemical
21synthesis, and includes any packaging or repackaging of the
22substance or labeling of its container, except that this term
23does not include:
24        (1) by an ultimate user, the preparation or compounding
25    of a controlled substance for his or her own use; or
26        (2) by a practitioner, or his or her authorized agent

 

 

10000SB2341sam001- 17 -LRB100 17957 JWD 39529 a

1    under his or her supervision, the preparation,
2    compounding, packaging, or labeling of a controlled
3    substance:
4            (a) as an incident to his or her administering or
5        dispensing of a controlled substance in the course of
6        his or her professional practice; or
7            (b) as an incident to lawful research, teaching or
8        chemical analysis and not for sale.
9    (z-1) (Blank).
10    (z-5) "Medication shopping" means the conduct prohibited
11under subsection (a) of Section 314.5 of this Act.
12    (z-10) "Mid-level practitioner" means (i) a physician
13assistant who has been delegated authority to prescribe through
14a written delegation of authority by a physician licensed to
15practice medicine in all of its branches, in accordance with
16Section 7.5 of the Physician Assistant Practice Act of 1987,
17(ii) an advanced practice registered nurse who has been
18delegated authority to prescribe through a written delegation
19of authority by a physician licensed to practice medicine in
20all of its branches or by a podiatric physician, in accordance
21with Section 65-40 of the Nurse Practice Act, (iii) an advanced
22practice registered nurse certified as a nurse practitioner,
23nurse midwife, or clinical nurse specialist who has been
24granted authority to prescribe by a hospital affiliate in
25accordance with Section 65-45 of the Nurse Practice Act, (iv)
26an animal euthanasia agency, or (v) a prescribing psychologist.

 

 

10000SB2341sam001- 18 -LRB100 17957 JWD 39529 a

1    (aa) "Narcotic drug" means any of the following, whether
2produced directly or indirectly by extraction from substances
3of vegetable origin, or independently by means of chemical
4synthesis, or by a combination of extraction and chemical
5synthesis:
6        (1) opium, opiates, derivatives of opium and opiates,
7    including their isomers, esters, ethers, salts, and salts
8    of isomers, esters, and ethers, whenever the existence of
9    such isomers, esters, ethers, and salts is possible within
10    the specific chemical designation; however the term
11    "narcotic drug" does not include the isoquinoline
12    alkaloids of opium;
13        (2) (blank);
14        (3) opium poppy and poppy straw;
15        (4) coca leaves, except coca leaves and extracts of
16    coca leaves from which substantially all of the cocaine and
17    ecgonine, and their isomers, derivatives and salts, have
18    been removed;
19        (5) cocaine, its salts, optical and geometric isomers,
20    and salts of isomers;
21        (6) ecgonine, its derivatives, their salts, isomers,
22    and salts of isomers;
23        (7) any compound, mixture, or preparation which
24    contains any quantity of any of the substances referred to
25    in subparagraphs (1) through (6).
26    (bb) "Nurse" means a registered nurse licensed under the

 

 

10000SB2341sam001- 19 -LRB100 17957 JWD 39529 a

1Nurse Practice Act.
2    (cc) (Blank).
3    (dd) "Opiate" means any substance having an addiction
4forming or addiction sustaining liability similar to morphine
5or being capable of conversion into a drug having addiction
6forming or addiction sustaining liability.
7    (ee) "Opium poppy" means the plant of the species Papaver
8somniferum L., except its seeds.
9    (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
10solution or other liquid form of medication intended for
11administration by mouth, but the term does not include a form
12of medication intended for buccal, sublingual, or transmucosal
13administration.
14    (ff) "Parole and Pardon Board" means the Parole and Pardon
15Board of the State of Illinois or its successor agency.
16    (gg) "Person" means any individual, corporation,
17mail-order pharmacy, government or governmental subdivision or
18agency, business trust, estate, trust, partnership or
19association, or any other entity.
20    (hh) "Pharmacist" means any person who holds a license or
21certificate of registration as a registered pharmacist, a local
22registered pharmacist or a registered assistant pharmacist
23under the Pharmacy Practice Act.
24    (ii) "Pharmacy" means any store, ship or other place in
25which pharmacy is authorized to be practiced under the Pharmacy
26Practice Act.

 

 

10000SB2341sam001- 20 -LRB100 17957 JWD 39529 a

1    (ii-5) "Pharmacy shopping" means the conduct prohibited
2under subsection (b) of Section 314.5 of this Act.
3    (ii-10) "Physician" (except when the context otherwise
4requires) means a person licensed to practice medicine in all
5of its branches.
6    (jj) "Poppy straw" means all parts, except the seeds, of
7the opium poppy, after mowing.
8    (kk) "Practitioner" means a physician licensed to practice
9medicine in all its branches, dentist, optometrist, podiatric
10physician, veterinarian, scientific investigator, pharmacist,
11physician assistant, advanced practice registered nurse,
12licensed practical nurse, registered nurse, emergency medical
13services personnel, hospital, laboratory, or pharmacy, or
14other person licensed, registered, or otherwise lawfully
15permitted by the United States or this State to distribute,
16dispense, conduct research with respect to, administer or use
17in teaching or chemical analysis, a controlled substance in the
18course of professional practice or research.
19    (ll) "Pre-printed prescription" means a written
20prescription upon which the designated drug has been indicated
21prior to the time of issuance; the term does not mean a written
22prescription that is individually generated by machine or
23computer in the prescriber's office.
24    (mm) "Prescriber" means a physician licensed to practice
25medicine in all its branches, dentist, optometrist,
26prescribing psychologist licensed under Section 4.2 of the

 

 

10000SB2341sam001- 21 -LRB100 17957 JWD 39529 a

1Clinical Psychologist Licensing Act with prescriptive
2authority delegated under Section 4.3 of the Clinical
3Psychologist Licensing Act, podiatric physician, or
4veterinarian who issues a prescription, a physician assistant
5who issues a prescription for a controlled substance in
6accordance with Section 303.05, a written delegation, and a
7written collaborative agreement required under Section 7.5 of
8the Physician Assistant Practice Act of 1987, an advanced
9practice registered nurse with prescriptive authority
10delegated under Section 65-40 of the Nurse Practice Act and in
11accordance with Section 303.05, a written delegation, and a
12written collaborative agreement under Section 65-35 of the
13Nurse Practice Act, an advanced practice registered nurse
14certified as a nurse practitioner, nurse midwife, or clinical
15nurse specialist who has been granted authority to prescribe by
16a hospital affiliate in accordance with Section 65-45 of the
17Nurse Practice Act and in accordance with Section 303.05, or an
18advanced practice registered nurse certified as a nurse
19practitioner, nurse midwife, or clinical nurse specialist who
20has full practice authority pursuant to Section 65-43 of the
21Nurse Practice Act.
22    (nn) "Prescription" means a written, facsimile, or oral
23order, or an electronic order that complies with applicable
24federal requirements, of a physician licensed to practice
25medicine in all its branches, dentist, podiatric physician or
26veterinarian for any controlled substance, of an optometrist in

 

 

10000SB2341sam001- 22 -LRB100 17957 JWD 39529 a

1accordance with Section 15.1 of the Illinois Optometric
2Practice Act of 1987, of a prescribing psychologist licensed
3under Section 4.2 of the Clinical Psychologist Licensing Act
4with prescriptive authority delegated under Section 4.3 of the
5Clinical Psychologist Licensing Act, of a physician assistant
6for a controlled substance in accordance with Section 303.05, a
7written delegation, and a written collaborative agreement
8required under Section 7.5 of the Physician Assistant Practice
9Act of 1987, of an advanced practice registered nurse with
10prescriptive authority delegated under Section 65-40 of the
11Nurse Practice Act who issues a prescription for a controlled
12substance in accordance with Section 303.05, a written
13delegation, and a written collaborative agreement under
14Section 65-35 of the Nurse Practice Act, of an advanced
15practice registered nurse certified as a nurse practitioner,
16nurse midwife, or clinical nurse specialist who has been
17granted authority to prescribe by a hospital affiliate in
18accordance with Section 65-45 of the Nurse Practice Act and in
19accordance with Section 303.05 when required by law, or of an
20advanced practice registered nurse certified as a nurse
21practitioner, nurse midwife, or clinical nurse specialist who
22has full practice authority pursuant to Section 65-43 of the
23Nurse Practice Act.
24    (nn-5) "Prescription Information Library" (PIL) means an
25electronic library that contains reported controlled substance
26data.

 

 

10000SB2341sam001- 23 -LRB100 17957 JWD 39529 a

1    (nn-10) "Prescription Monitoring Program" (PMP) means the
2entity that collects, tracks, and stores reported data on
3controlled substances and select drugs pursuant to Section 316.
4    (oo) "Production" or "produce" means manufacture,
5planting, cultivating, growing, or harvesting of a controlled
6substance other than methamphetamine.
7    (pp) "Registrant" means every person who is required to
8register under Section 302 of this Act.
9    (qq) "Registry number" means the number assigned to each
10person authorized to handle controlled substances under the
11laws of the United States and of this State.
12    (qq-5) "Secretary" means, as the context requires, either
13the Secretary of the Department or the Secretary of the
14Department of Financial and Professional Regulation, and the
15Secretary's designated agents.
16    (rr) "State" includes the State of Illinois and any state,
17district, commonwealth, territory, insular possession thereof,
18and any area subject to the legal authority of the United
19States of America.
20    (rr-5) "Stimulant" means any drug that (i) causes an
21overall excitation of central nervous system functions, (ii)
22causes impaired consciousness and awareness, and (iii) can be
23habit-forming or lead to a substance abuse problem, including
24but not limited to amphetamines and their analogs,
25methylphenidate and its analogs, cocaine, and phencyclidine
26and its analogs.

 

 

10000SB2341sam001- 24 -LRB100 17957 JWD 39529 a

1    (rr-10) "Synthetic drug" includes, but is not limited to,
2any synthetic cannabinoids or piperazines or any synthetic
3cathinones as provided for in Schedule I.
4    (ss) "Ultimate user" means a person who lawfully possesses
5a controlled substance for his or her own use or for the use of
6a member of his or her household or for administering to an
7animal owned by him or her or by a member of his or her
8household.
9(Source: P.A. 99-78, eff. 7-20-15; 99-173, eff. 7-29-15;
1099-371, eff. 1-1-16; 99-480, eff. 9-9-15; 99-642, eff. 7-28-16;
11100-280, eff. 1-1-18; 100-453, eff. 8-25-17; 100-513, eff.
121-1-18; revised 10-6-17.)
 
13    (720 ILCS 570/204)  (from Ch. 56 1/2, par. 1204)
14    Sec. 204. (a) The controlled substances listed in this
15Section are included in Schedule I.
16    (b) Unless specifically excepted or unless listed in
17another schedule, any of the following opiates, including their
18isomers, esters, ethers, salts, and salts of isomers, esters,
19and ethers, whenever the existence of such isomers, esters,
20ethers and salts is possible within the specific chemical
21designation:
22        (1) Acetylmethadol;
23        (1.1) Acetyl-alpha-methylfentanyl
24    (N-[1-(1-methyl-2-phenethyl)-
25    4-piperidinyl]-N-phenylacetamide);

 

 

10000SB2341sam001- 25 -LRB100 17957 JWD 39529 a

1        (2) Allylprodine;
2        (3) Alphacetylmethadol, except
3    levo-alphacetylmethadol (also known as levo-alpha-
4    acetylmethadol, levomethadyl acetate, or LAAM);
5        (4) Alphameprodine;
6        (5) Alphamethadol;
7        (6) Alpha-methylfentanyl
8    (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
9    propionanilide;  1-(1-methyl-2-phenylethyl)-4-(N-
10    propanilido) piperidine;
11        (6.1) Alpha-methylthiofentanyl
12    (N-[1-methyl-2-(2-thienyl)ethyl-
13    4-piperidinyl]-N-phenylpropanamide);
14        (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
15        (7.1) PEPAP
16    (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
17        (8) Benzethidine;
18        (9) Betacetylmethadol;
19        (9.1) Beta-hydroxyfentanyl
20    (N-[1-(2-hydroxy-2-phenethyl)-
21    4-piperidinyl]-N-phenylpropanamide);
22        (10) Betameprodine;
23        (11) Betamethadol;
24        (12) Betaprodine;
25        (13) Clonitazene;
26        (14) Dextromoramide;

 

 

10000SB2341sam001- 26 -LRB100 17957 JWD 39529 a

1        (15) Diampromide;
2        (16) Diethylthiambutene;
3        (17) Difenoxin;
4        (18) Dimenoxadol;
5        (19) Dimepheptanol;
6        (20) Dimethylthiambutene;
7        (21) Dioxaphetylbutyrate;
8        (22) Dipipanone;
9        (23) Ethylmethylthiambutene;
10        (24) Etonitazene;
11        (25) Etoxeridine;
12        (26) Furethidine;
13        (27) Hydroxpethidine;
14        (28) Ketobemidone;
15        (29) Levomoramide;
16        (30) Levophenacylmorphan;
17        (31) 3-Methylfentanyl
18    (N-[3-methyl-1-(2-phenylethyl)-
19    4-piperidyl]-N-phenylpropanamide);
20        (31.1) 3-Methylthiofentanyl
21    (N-[(3-methyl-1-(2-thienyl)ethyl-
22    4-piperidinyl]-N-phenylpropanamide);
23        (32) Morpheridine;
24        (33) Noracymethadol;
25        (34) Norlevorphanol;
26        (35) Normethadone;

 

 

10000SB2341sam001- 27 -LRB100 17957 JWD 39529 a

1        (36) Norpipanone;
2        (36.1) Para-fluorofentanyl
3    (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
4    4-piperidinyl]propanamide);
5        (37) Phenadoxone;
6        (38) Phenampromide;
7        (39) Phenomorphan;
8        (40) Phenoperidine;
9        (41) Piritramide;
10        (42) Proheptazine;
11        (43) Properidine;
12        (44) Propiram;
13        (45) Racemoramide;
14        (45.1) Thiofentanyl
15    (N-phenyl-N-[1-(2-thienyl)ethyl-
16    4-piperidinyl]-propanamide);
17        (46) Tilidine;
18        (47) Trimeperidine;
19        (48) Beta-hydroxy-3-methylfentanyl (other name:
20    N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
21    N-phenylpropanamide);
22        (49) Furanyl fentanyl (FU-F);
23        (50) Butyryl fentanyl;
24        (51) Valeryl fentanyl;
25        (52) Acetyl fentanyl;
26        (53) Beta-hydroxy-thiofentanyl;

 

 

10000SB2341sam001- 28 -LRB100 17957 JWD 39529 a

1        (54) 3,4-dichloro-N-[2-
2    (dimethylamino)cyclohexyl]-N-
3    methylbenzamide (U-47700); 
4        (55) 4-chloro-N-[1-[2-
5    (4-nitrophenyl)ethyl]-2-piperidinylidene]-
6    benzenesulfonamide (W-18); 
7        (56) 4-chloro-N-[1-(2-phenylethyl)
8    -2-piperidinylidene]-benzenesulfonamide (W-15); 
9        (57) acrylfentanyl (acryloylfentanyl). 
10    (c) Unless specifically excepted or unless listed in
11another schedule, any of the following opium derivatives, its
12salts, isomers and salts of isomers, whenever the existence of
13such salts, isomers and salts of isomers is possible within the
14specific chemical designation:
15        (1) Acetorphine;
16        (2) Acetyldihydrocodeine;
17        (3) Benzylmorphine;
18        (4) Codeine methylbromide;
19        (5) Codeine-N-Oxide;
20        (6) Cyprenorphine;
21        (7) Desomorphine;
22        (8) Diacetyldihydromorphine (Dihydroheroin);
23        (9) Dihydromorphine;
24        (10) Drotebanol;
25        (11) Etorphine (except hydrochloride salt);
26        (12) Heroin;

 

 

10000SB2341sam001- 29 -LRB100 17957 JWD 39529 a

1        (13) Hydromorphinol;
2        (14) Methyldesorphine;
3        (15) Methyldihydromorphine;
4        (16) Morphine methylbromide;
5        (17) Morphine methylsulfonate;
6        (18) Morphine-N-Oxide;
7        (19) Myrophine;
8        (20) Nicocodeine;
9        (21) Nicomorphine;
10        (22) Normorphine;
11        (23) Pholcodine;
12        (24) Thebacon.
13    (d) Unless specifically excepted or unless listed in
14another schedule, any material, compound, mixture, or
15preparation which contains any quantity of the following
16hallucinogenic substances, or which contains any of its salts,
17isomers and salts of isomers, whenever the existence of such
18salts, isomers, and salts of isomers is possible within the
19specific chemical designation (for the purposes of this
20paragraph only, the term "isomer" includes the optical,
21position and geometric isomers):
22        (1) 3,4-methylenedioxyamphetamine
23    (alpha-methyl,3,4-methylenedioxyphenethylamine,
24    methylenedioxyamphetamine, MDA);
25        (1.1) Alpha-ethyltryptamine
26    (some trade or other names: etryptamine;

 

 

10000SB2341sam001- 30 -LRB100 17957 JWD 39529 a

1    MONASE; alpha-ethyl-1H-indole-3-ethanamine;
2    3-(2-aminobutyl)indole; a-ET; and AET);
3        (2) 3,4-methylenedioxymethamphetamine (MDMA);
4        (2.1) 3,4-methylenedioxy-N-ethylamphetamine
5    (also known as: N-ethyl-alpha-methyl-
6    3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
7    and MDEA);
8        (2.2) N-Benzylpiperazine (BZP);
9        (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
10        (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
11        (4) 3,4,5-trimethoxyamphetamine (TMA);
12        (5) (Blank);
13        (6) Diethyltryptamine (DET);
14        (7) Dimethyltryptamine (DMT);
15        (7.1) 5-Methoxy-diallyltryptamine;
16        (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
17        (9) Ibogaine  (some trade and other names:
18    7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
19    6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
20    indole; Tabernanthe iboga);
21        (10) Lysergic acid diethylamide;
22        (10.1) Salvinorin A;
23        (10.5) Salvia divinorum (meaning all parts of the plant
24    presently classified botanically as Salvia divinorum,
25    whether growing or not, the seeds thereof, any extract from
26    any part of that plant, and every compound, manufacture,

 

 

10000SB2341sam001- 31 -LRB100 17957 JWD 39529 a

1    salts, isomers, and salts of isomers whenever the existence
2    of such salts, isomers, and salts of isomers is possible
3    within the specific chemical designation, derivative,
4    mixture, or preparation of that plant, its seeds or
5    extracts);
6        (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
7        (12) Peyote (meaning all parts of the plant presently
8    classified botanically as Lophophora williamsii Lemaire,
9    whether growing or not, the seeds thereof, any extract from
10    any part of that plant, and every compound, manufacture,
11    salts, derivative, mixture, or preparation of that plant,
12    its seeds or extracts);
13        (13) N-ethyl-3-piperidyl benzilate (JB 318);
14        (14) N-methyl-3-piperidyl benzilate;
15        (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
16    (also known as N-hydroxy-alpha-methyl-
17    3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
18        (15) Parahexyl; some trade or other names:
19    3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
20    dibenzo (b,d) pyran; Synhexyl;
21        (16) Psilocybin;
22        (17) Psilocyn;
23        (18) Alpha-methyltryptamine (AMT);
24        (19) 2,5-dimethoxyamphetamine
25    (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
26        (20) 4-bromo-2,5-dimethoxyamphetamine

 

 

10000SB2341sam001- 32 -LRB100 17957 JWD 39529 a

1    (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
2    4-bromo-2,5-DMA);
3        (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
4    Some trade or other names: 2-(4-bromo-
5    2,5-dimethoxyphenyl)-1-aminoethane;
6    alpha-desmethyl DOB, 2CB, Nexus;
7        (21) 4-methoxyamphetamine
8    (4-methoxy-alpha-methylphenethylamine;
9    paramethoxyamphetamine; PMA);
10        (22) (Blank);
11        (23) Ethylamine analog of phencyclidine.
12    Some trade or other names:
13    N-ethyl-1-phenylcyclohexylamine,
14    (1-phenylcyclohexyl) ethylamine,
15    N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
16        (24) Pyrrolidine analog of phencyclidine. Some trade
17    or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
18    PHP;
19        (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
20        (26) 2,5-dimethoxy-4-ethylamphetamine
21    (another name: DOET);
22        (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
23    (another name: TCPy);
24        (28) (Blank);
25        (29) Thiophene analog of phencyclidine (some trade
26    or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;

 

 

10000SB2341sam001- 33 -LRB100 17957 JWD 39529 a

1    2-thienyl analog of phencyclidine; TPCP; TCP);
2        (29.1) Benzothiophene analog of phencyclidine. Some
3    trade or other names: BTCP or benocyclidine;
4        (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
5        (30) Bufotenine (some trade or other names:
6    3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
7    3-(2-dimethylaminoethyl)-5-indolol;
8    5-hydroxy-N,N-dimethyltryptamine;
9    N,N-dimethylserotonin; mappine);
10        (31) (Blank);  
11        (32) (Blank);  
12        (33) (Blank);  
13        (34) (Blank); 
14        (34.5) (Blank);  
15        (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
16    (2-methyloctan-2-yl)-6a,7, 
17    10,10a-tetrahydrobenzo[c]chromen-1-ol
18    Some trade or other names: HU-210; 
19        (35.5)  (6aS,10aS)-9-(hydroxymethyl)-6,6- 
20    dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
21    tetrahydrobenzo[c]chromen-1-ol, its isomers,  
22    salts, and salts of isomers; Some trade or other  
23    names: HU-210, Dexanabinol; 
24        (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
25    6,6-dimethyl-3-(2-methyloctan-2-yl)- 
26    6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol

 

 

10000SB2341sam001- 34 -LRB100 17957 JWD 39529 a

1    Some trade or other names: HU-211;
2        (37) (Blank);
3        (38) (Blank);
4        (39) (Blank);
5        (40) (Blank);
6        (41) (Blank);
7        (42) Any compound structurally derived from
8    3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane
9    by substitution at the nitrogen atom of the indole ring by
10    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
11    cycloalkylethyl, aryl halide, alkyl aryl halide,
12    1-(N-methyl-2-piperidinyl)methyl, or
13    2-(4-morpholinyl)ethyl whether or not further substituted
14    in the indole ring to any extent, whether or not
15    substituted in the naphthyl ring to any extent. Examples of
16    this structural class include, but are not limited to,
17    JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
18        (43) Any compound structurally derived from
19    3-(1-naphthoyl)pyrrole by substitution at the nitrogen
20    atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
21    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
22    halide, 1-(N-methyl-2-piperidinyl)methyl, or
23    2-(4-morpholinyl)ethyl, whether or not further substituted
24    in the pyrrole ring to any extent, whether or not
25    substituted in the naphthyl ring to any extent. Examples of
26    this structural class include, but are not limited to,

 

 

10000SB2341sam001- 35 -LRB100 17957 JWD 39529 a

1    JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
2        (44) Any compound structurally derived from
3    1-(1-naphthylmethyl)indene by substitution at the
4    3-position of the indene ring by alkyl, haloalkyl, alkenyl,
5    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
6    halide, 1-(N-methyl-2-piperidinyl)methyl, or
7    2-(4-morpholinyl)ethyl whether or not further substituted
8    in the indene ring to any extent, whether or not
9    substituted in the naphthyl ring to any extent. Examples of
10    this structural class include, but are not limited to,
11    JWH-176;
12        (45) Any compound structurally derived from
13    3-phenylacetylindole by substitution at the nitrogen atom
14    of the indole ring with alkyl, haloalkyl, alkenyl,
15    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
16    halide, 1-(N-methyl-2-piperidinyl)methyl, or
17    2-(4-morpholinyl)ethyl, whether or not further substituted
18    in the indole ring to any extent, whether or not
19    substituted in the phenyl ring to any extent. Examples of
20    this structural class include, but are not limited to,
21    JWH-167, JWH-250, JWH-251, and RCS-8;
22        (46) Any compound structurally derived from
23    2-(3-hydroxycyclohexyl)phenol by substitution at the
24    5-position of the phenolic ring by alkyl, haloalkyl,
25    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
26    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or

 

 

10000SB2341sam001- 36 -LRB100 17957 JWD 39529 a

1    2-(4-morpholinyl)ethyl, whether or not substituted in the
2    cyclohexyl ring to any extent. Examples of this structural
3    class include, but are not limited to, CP 47, 497 and its
4    C8 homologue (cannabicyclohexanol);
5        (46.1) Any compound structurally derived from
6    3-(benzoyl) indole with substitution at the nitrogen atom
7    of the indole ring by an alkyl, haloalkyl, alkenyl,
8    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
9    halide, 1-(N-methyl-2-piperidinyl)methyl, or
10    2-(4-morpholinyl)ethyl group whether or not further
11    substituted in the indole ring to any extent and whether or
12    not substituted in the phenyl ring to any extent. Examples
13    of this structural class include, but are not limited to,
14    AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and
15    RCS-4;
16        (47) (Blank);
17        (48) (Blank);
18        (49) (Blank);
19        (50) (Blank);
20        (51) (Blank);
21        (52) (Blank);
22        (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
23    Some trade or other names: 2C-T-7;
24        (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some trade
25    or other names: 2C-E;
26        (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some

 

 

10000SB2341sam001- 37 -LRB100 17957 JWD 39529 a

1    trade or other names: 2C-D;
2        (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
3    trade or other names: 2C-C;
4        (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
5    or other names: 2C-I;
6        (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
7    trade or other names: 2C-T-2;
8        (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
9    Some trade or other names: 2C-T-4;
10        (53.7) 2,5-dimethoxyphenethylamine. Some trade or
11    other names: 2C-H;
12        (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some trade
13    or other names: 2C-N;
14        (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
15    trade or other names: 2C-P;
16        (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. Some
17    trade or other names: 2C-G;
18        (53.11) The N-(2-methoxybenzyl) derivative of any 2C
19    phenethylamine referred to in subparagraphs (20.1), (53),
20    (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
21    (53.8), (53.9), and (53.10) including, but not limited to,
22    25I-NBOMe and 25C-NBOMe;
23        (54) 5-Methoxy-N,N-diisopropyltryptamine;
24        (55) (Blank);
25        (56) (Blank);
26        (57) (Blank);

 

 

10000SB2341sam001- 38 -LRB100 17957 JWD 39529 a

1        (58) (Blank);
2        (59) 3-cyclopropoylindole with substitution at the
3    nitrogen atom of the indole ring by alkyl, haloalkyl,
4    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
5    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
6    2-(4-morpholinyl)ethyl, whether or not further substituted
7    on the indole ring to any extent, whether or not
8    substituted on the cyclopropyl ring to any extent:
9    including, but not limited to, XLR11, UR144, FUB-144;
10        (60) 3-adamantoylindole with substitution at the
11    nitrogen atom of the indole ring by alkyl, haloalkyl,
12    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
13    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
14    2-(4-morpholinyl)ethyl, whether or not further substituted
15    on the indole ring to any extent, whether or not
16    substituted on the adamantyl ring to any extent: including,
17    but not limited to, AB-001;
18        (61) N-(adamantyl)-indole-3-carboxamide with
19    substitution at the nitrogen atom of the indole ring by
20    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
21    cycloalkylethyl, aryl halide, alkyl aryl halide,
22    1-(N-methyl-2-piperidinyl)methyl, or
23    2-(4-morpholinyl)ethyl, whether or not further substituted
24    on the indole ring to any extent, whether or not
25    substituted on the adamantyl ring to any extent: including,
26    but not limited to, APICA/2NE-1, STS-135;

 

 

10000SB2341sam001- 39 -LRB100 17957 JWD 39529 a

1        (62) N-(adamantyl)-indazole-3-carboxamide with
2    substitution at a nitrogen atom of the indazole ring by
3    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
4    cycloalkylethyl, aryl halide, alkyl aryl halide,
5    1-(N-methyl-2-piperidinyl)methyl, or
6    2-(4-morpholinyl)ethyl, whether or not further substituted
7    on the indazole ring to any extent, whether or not
8    substituted on the adamantyl ring to any extent: including,
9    but not limited to, AKB48, 5F-AKB48;
10        (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
11    with substitution at the nitrogen atom of the indole ring
12    by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
13    cycloalkylethyl, aryl halide, alkyl aryl halide,
14    1-(N-methyl-2-piperidinyl)methyl, or
15    2-(4-morpholinyl)ethyl, whether or not further substituted
16    on the indole ring to any extent, whether or not
17    substituted on the quinoline ring to any extent: including,
18    but not limited to, PB22, 5F-PB22, FUB-PB-22;
19        (64) 3-(1-naphthoyl)indazole with substitution at the
20    nitrogen atom of the indazole ring by alkyl, haloalkyl,
21    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
22    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
23    2-(4-morpholinyl)ethyl, whether or not further substituted
24    on the indazole ring to any extent, whether or not
25    substituted on the naphthyl ring to any extent: including,
26    but not limited to, THJ-018, THJ-2201;

 

 

10000SB2341sam001- 40 -LRB100 17957 JWD 39529 a

1        (65) 2-(1-naphthoyl)benzimidazole with substitution at
2    the nitrogen atom of the benzimidazole ring by alkyl,
3    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
4    aryl halide, alkyl aryl halide,
5    1-(N-methyl-2-piperidinyl)methyl, or
6    2-(4-morpholinyl)ethyl, whether or not further substituted
7    on the benzimidazole ring to any extent, whether or not
8    substituted on the naphthyl ring to any extent: including,
9    but not limited to, FUBIMINA;
10        (66) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
11    3-carboxamide with substitution on the nitrogen atom of the
12    indazole ring by alkyl, haloalkyl, alkenyl,
13    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
14    halide, 1-(N-methyl-2-piperidinyl)methyl, or
15    2-(4-morpholinyl)ethyl, whether or not further substituted
16    on the indazole ring to any extent: including, but not
17    limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
18        (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
19    indazole-3-carboxamide with substitution on the nitrogen
20    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
21    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
22    halide, 1-(N-methyl-2-piperidinyl)methyl, or
23    2-(4-morpholinyl)ethyl, whether or not further substituted
24    on the indazole ring to any extent: including, but not
25    limited to, ADB-PINACA, ADB-FUBINACA;
26        (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-

 

 

10000SB2341sam001- 41 -LRB100 17957 JWD 39529 a

1    indole-3-carboxamide with substitution on the nitrogen
2    atom of the indole ring by alkyl, haloalkyl, alkenyl,
3    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
4    halide, 1-(N-methyl-2-piperidinyl)methyl, or
5    2-(4-morpholinyl)ethyl, whether or not further substituted
6    on the indole ring to any extent: including, but not
7    limited to, ADBICA, 5F-ADBICA;
8        (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
9    3-carboxamide with substitution on the nitrogen atom of the
10    indole ring by alkyl, haloalkyl, alkenyl,
11    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
12    halide, 1-(N-methyl-2-piperidinyl)methyl, or
13    2-(4-morpholinyl)ethyl, whether or not further substituted
14    on the indole ring to any extent: including, but not
15    limited to, ABICA, 5F-ABICA;
16        (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
17    methylbutanoate with substitution on the nitrogen atom of
18    the indazole ring by alkyl, haloalkyl, alkenyl,
19    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
20    halide, 1-(N-methyl-2-piperidinyl)methyl, or
21    2-(4-morpholinyl)ethyl, whether or not further substituted
22    on the indazole ring to any extent: including, but not
23    limited to, AMB, 5F-AMB; .
24        (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
25    dimethylbutanoate with substitution on the nitrogen atom
26    of the indazole ring by alkyl, haloalkyl, alkenyl,

 

 

10000SB2341sam001- 42 -LRB100 17957 JWD 39529 a

1    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
2    halide, 1-(N-methyl-2-piperidinyl)methyl, or
3    2-(4-morpholinyl)ethyl, whether or not further substituted
4    on the indazole ring to any extent: including, but not
5    limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
6        (72) Methyl 2-(1H-indole-3-carboxamido)-3-
7    methylbutanoate with substitution on the nitrogen atom of
8    the indole ring by alkyl, haloalkyl, alkenyl,
9    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
10    halide, 1-(N-methyl-2-piperidinyl)methyl, or
11    2-(4-morpholinyl)ethyl, whether or not further substituted
12    on the indazole ring to any extent: including, but not
13    limited to, MMB018, MMB2201, and AMB-CHMICA;
14        (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
15    dimethylbutanoate with substitution on the nitrogen atom
16    of the indole ring by alkyl, haloalkyl, alkenyl,
17    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
18    halide, 1-(N-methyl-2-piperidinyl)methyl, or
19    2-(4-morpholinyl)ethyl, whether or not further substituted
20    on the indazole ring to any extent: including, but not
21    limited to, MDMB-CHMICA;
22        (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
23    indazole-3-carboxamide with substitution on the nitrogen
24    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
25    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
26    halide, 1-(N-methyl-2-piperidinyl)methyl, or

 

 

10000SB2341sam001- 43 -LRB100 17957 JWD 39529 a

1    2-(4-morpholinyl)ethyl, whether or not further substituted
2    on the indazole ring to any     extent: including, but not
3    limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
4        (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
5    3-carboxamide with substitution on the nitrogen atom of the
6    indole ring by alkyl, haloalkyl, alkenyl,
7    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
8    halide, 1-(N-methyl-2-piperidinyl)methyl, or
9    2-(4-morpholinyl)ethyl, whether or not further substituted
10    on the indazole ring to any extent: including, but not
11    limited to, APP-PICA and 5-fluoro-APP-PICA;
12        (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
13    4-AcO-DMT;
14        (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
15    name 5-MeO-MIPT;
16        (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
17        (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
18        (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
19        (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
20    (4-HO-MiPT);
21        (82) Fluorophenylpiperazine;
22        (83) Methoxetamine;
23        (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
24    ethcathinone).
25    (e) Unless specifically excepted or unless listed in
26another schedule, any material, compound, mixture, or

 

 

10000SB2341sam001- 44 -LRB100 17957 JWD 39529 a

1preparation which contains any quantity of the following
2substances having a depressant effect on the central nervous
3system, including its salts, isomers, and salts of isomers
4whenever the existence of such salts, isomers, and salts of
5isomers is possible within the specific chemical designation:
6        (1) mecloqualone;
7        (2) methaqualone; and
8        (3) gamma hydroxybutyric acid.
9    (f) Unless specifically excepted or unless listed in
10another schedule, any material, compound, mixture, or
11preparation which contains any quantity of the following
12substances having a stimulant effect on the central nervous
13system, including its salts, isomers, and salts of isomers:
14        (1) Fenethylline;
15        (2) N-ethylamphetamine;
16        (3) Aminorex (some other names:
17    2-amino-5-phenyl-2-oxazoline; aminoxaphen;
18    4-5-dihydro-5-phenyl-2-oxazolamine) and its
19    salts, optical isomers, and salts of optical isomers;
20        (4) Methcathinone (some other names:
21    2-methylamino-1-phenylpropan-1-one;
22    Ephedrone; 2-(methylamino)-propiophenone;
23    alpha-(methylamino)propiophenone; N-methylcathinone;
24    methycathinone; Monomethylpropion; UR 1431) and its
25    salts, optical isomers, and salts of optical isomers;
26        (5) Cathinone (some trade or other names:

 

 

10000SB2341sam001- 45 -LRB100 17957 JWD 39529 a

1    2-aminopropiophenone; alpha-aminopropiophenone;
2    2-amino-1-phenyl-propanone; norephedrone);
3        (6) N,N-dimethylamphetamine (also known as:
4    N,N-alpha-trimethyl-benzeneethanamine;
5    N,N-alpha-trimethylphenethylamine);
6        (7) (+ or -) cis-4-methylaminorex  ((+ or -) cis-
7    4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
8        (8) 3,4-Methylenedioxypyrovalerone (MDPV);
9        (9) Halogenated amphetamines and
10    methamphetamines - any compound derived from either
11    amphetamine or methamphetamine through the substitution
12    of a halogen on the phenyl ring, including, but not
13    limited to, 2-fluoroamphetamine, 3-
14    fluoroamphetamine and 4-fluoroamphetamine; 
15        (10) Aminopropylbenzofuran (APB):
16    including 4-(2-Aminopropyl) benzofuran, 5-
17    (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
18    benzofuran, and 7-(2-Aminopropyl) benzofuran; 
19        (11) Aminopropyldihydrobenzofuran (APDB):
20    including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
21    5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
22    6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
23    and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; 
24        (12) Methylaminopropylbenzofuran
25    (MAPB): including 4-(2-methylaminopropyl)
26    benzofuran, 5-(2-methylaminopropyl)benzofuran,

 

 

10000SB2341sam001- 46 -LRB100 17957 JWD 39529 a

1    6-(2-methylaminopropyl)benzofuran
2    and 7-(2-methylaminopropyl)benzofuran. 
3    (g) Temporary listing of substances subject to emergency
4scheduling. Any material, compound, mixture, or preparation
5that contains any quantity of the following substances:
6        (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
7    (benzylfentanyl), its optical isomers, isomers, salts, and
8    salts of isomers;
9        (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
10    phenylpropanamide (thenylfentanyl), its optical isomers,
11    salts, and salts of isomers.
12    (h) Synthetic cathinones. Unless specifically excepted,
13any chemical compound which is not approved by the United
14States Food and Drug Administration or, if approved, is not
15dispensed or possessed in accordance with State or federal law,
16not including bupropion, structurally derived from
172-aminopropan-1-one by substitution at the 1-position with
18either phenyl, naphthyl, or thiophene ring systems, whether or
19not the compound is further modified in one or more of the
20following ways:
21        (1) by substitution in the ring system to any extent
22    with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
23    halide substituents, whether or not further substituted in
24    the ring system by one or more other univalent
25    substituents. Examples of this class include, but are not
26    limited to, 3,4-Methylenedioxycathinone (bk-MDA);

 

 

10000SB2341sam001- 47 -LRB100 17957 JWD 39529 a

1        (2) by substitution at the 3-position with an acyclic
2    alkyl substituent. Examples of this class include, but are
3    not limited to, 2-methylamino-1-phenylbutan-1-one
4    (buphedrone); or
5        (3) by substitution at the 2-amino nitrogen atom with
6    alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
7    inclusion of the 2-amino nitrogen atom in a cyclic
8    structure. Examples of this class include, but are not
9    limited to, Dimethylcathinone, Ethcathinone, and
10    a-Pyrrolidinopropiophenone (a-PPP); or .
11    Any other synthetic cathinone which is not approved by the
12United States Food and Drug Administration or, if approved, is
13not dispensed or possessed in accordance with State or federal
14law.
15    (i) Synthetic cannabinoids or piperazines. Any synthetic
16cannabinoid or piperazine which is not approved by the United
17States Food and Drug Administration or, if approved, which is
18not dispensed or possessed in accordance with State and federal
19law.
20(Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
21100-368, eff. 1-1-18; revised 10-5-17.)".